Asieris

Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023

by

SHANGHAI, May 31, 2023 /PRNewswire/ — Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology (ASCO) … Read more

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

by

SHANGHAI, May 18, 2023 /PRNewswire/ — Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation (“UroViu”). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu’s patented technology of portable single-use cystoscope in … Read more